July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Acceptability of OCT Angiography: A multicentre OCT Angiography NEtwork (OCTANE) study.
Author Affiliations & Notes
  • Faruque Ghanchi
    Ophthalmology, Bradford Teaching Hospitals, Bradford, West Yorkshire, United Kingdom
    University of Bradford, United Kingdom
  • Corinne Fulcher
    Ophthalmology, Bradford Teaching Hospitals, Bradford, West Yorkshire, United Kingdom
  • Sobha Sivaprasad
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Konstantinos Balaskas
    NIHR Moorfields Biomedical Research Centre, London, United Kingdom
  • Richard Peter Gale
    York Teaching Hospital, York, United Kingdom
    University of York, York, United Kingdom
  • Gabriella De Salvo
    University Hospital Southampton, Southampton, United Kingdom
  • James S Talks
    Royal Victoria Infirmary, Newcastle, United Kingdom
  • Andrew Lotery
    University Hospital Southampton, Southampton, United Kingdom
  • Ian A Pearce
    St Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom
  • Footnotes
    Commercial Relationships   Faruque Ghanchi, Allergan (R), Allimera (R), Bayer Ltd (F), Bayer Ltd (R), Heidleberg (R), Novartis (R), Roche (R); Corinne Fulcher, None; Sobha Sivaprasad, Allergan (F), Allergan (R), Bayer (F), Bayer (R), Boehringer Ingleheim (F), Boehringer Ingleheim (R), Heidleberg (F), Heidleberg (R), Novartis (F), Novartis (R), Optos (F), Optos (R), Roche (F), Roche (R); Konstantinos Balaskas, Heidleberg (R), Topcon (R); Richard Gale, Bayer (F), Bayer (C), Bayer (R); Gabriella De Salvo, Allergan (R), Bayer (R), Heidleberg (R), Novartis (R); James Talks, Bayer (F), Bayer (R), Novartis (F), Novartis (R); Andrew Lotery, None; Ian Pearce, Allergan (R), Bayer (F), Bayer (R), Heidleberg (R), Novartis (R)
  • Footnotes
    Support  Bayer UK Ltd. and NIHR (UK)
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 3477. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Faruque Ghanchi, Corinne Fulcher, Sobha Sivaprasad, Konstantinos Balaskas, Richard Peter Gale, Gabriella De Salvo, James S Talks, Andrew Lotery, Ian A Pearce; Acceptability of OCT Angiography: A multicentre OCT Angiography NEtwork (OCTANE) study.. Invest. Ophthalmol. Vis. Sci. 2019;60(9):3477. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Spectral Domain OCT angiography (OCT-A) provides high resolution imaging of the chorio-retinal vasculature and may be used as a non-invasive alternative to diagnostic retinal dye angiography. The OCTANE study is first study to define feasibility of using OCT-A within a busy, real-world clinical setting. The purpose was to define acceptability of OCTA by patients and technicians in routine clinical practice.

Methods : Following ethical approval, patients attending for the care of a retinal condition at one of seven UK hospitals were randomly recruited. 284 patients underwent standardised imaging including OCT-A with Spectralis (Heidelberg Engineering, Germany). Patient and technician feedback was collected on a standardised questionnaire, designed for this study. Analysis was divided into “patient” and “technician” acceptability. 51 patients were excluded due to incomplete data, and a further 5 were excluded from the patient analysis due incomplete questionnaire. Thus 233 patients were included in the patient feasibility analysis and 238 in the technician feasibility analysis.

Results : The mean age of patients was 64.2 years (range 22 – 94 years) and 47.5% were female. 30% of patients had age-related macular degeneration, 20% had diabetic eye disease, 10% had retinal vein occlusion and 40% other retinal pathology (Fig. 1). Visual acuity across all eyes tested ranged from Snellen acuity of 6/3 to no perception of light. From the patient analysis (n=233), 85.8% of patients found OCT-A to be acceptable with 96.6% reporting that they would have the test again. 92.3% also agreed that the test was comfortable. Amongst the technician analysis (n=238), there were no reported problems in 79.8% of cases (Fig. 2). Common difficulties reported were due to poor patient fixation and long acquisition time. No adverse events were reported.

Conclusions : In diverse patient population Spectralis OCT-A was found to be well accepted by both patients and technicians in routine clinical practice at seven UK hospitals. OCT-A has potential to be a routine clinical test in retina practice.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

 

Figure 1: Patient diagnosis

Figure 1: Patient diagnosis

 

Figure 2. Patient and Technician feedback

Figure 2. Patient and Technician feedback

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×